Luc Tritsmans

Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer’s disease: randomized, double-blind, placebo-controlled study

Maarten Timmers, Johannes Streffer, Alberto Russu et al. · Alzheimer s Research & Therapy · 2018 · 112 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer’s disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension study

Gerald Novak, Johannes Streffer, Maarten Timmers et al. · Alzheimer s Research & Therapy · 2020 · 105 citations · Full text

Medicine, Neurology, Pharmacology +17

JC Virus Quasispecies Analysis Reveals a Complex Viral Population Underlying Progressive Multifocal Leukoencephalopathy and Supports Viral Dissemination via the Hematogenous Route

Tom Van Loy, Kim Thys, Caroline F. Ryschkewitsch et al. · Journal of Virology · 2014 · 63 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +17

Profiling the dynamics of CSF and plasma Aβ reduction after treatment with JNJ‐54861911, a potent oral BACE inhibitor

Maarten Timmers, Bianca Van Broeck, Steven Ramael et al. · Alzheimer s & Dementia Translational Research & Clinical Interventions · 2016 · 60 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +7

Discovery of Atabecestat (JNJ-54861911): A Thiazine-Based β-Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor Advanced to the Phase 2b/3 EARLY Clinical Trial

Yuji Koriyama, Akihiro Hori, Hisanori Ito et al. · Journal of Medicinal Chemistry · 2021 · 54 citations · Full text

Life Sciences, Medicinal Chemistry, Pharmacology +17